{"id":"W4379276081","doi":"10.33380/2305-2066-2023-12-2-146-153","title":"Phase I Pharmacokinetics Study of Drug for Infusion «Areplivir» (INN: Favipiravir) (LLC \"PROMOMED RUS\", Russia)","year":2023,"lang":"en","type":"article","venue":"Drug development & registration","topic":"Drug-Induced Hepatotoxicity and Protection","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Pharmacokinetics; Pharmacology; Drug; Medicine; Favipiravir; Coronavirus disease 2019 (COVID-19); Internal medicine; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002641214,0.0003946033,0.0004418093,0.0004368708,0.000721536,0.00005215398,0.0003538601,0.000250034,0.0001791005],"category_scores_gemma":[0.0001317643,0.0004143557,0.0001164943,0.0009131405,0.0001029037,0.0002841548,0.0001127092,0.0006237597,0.0001309879],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001768876,"about_ca_system_score_gemma":0.0002991573,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005354553,"about_ca_topic_score_gemma":0.0001824272,"domain_scores_codex":[0.9966987,0.0004652461,0.001096107,0.0006510561,0.0005198503,0.0005690653],"domain_scores_gemma":[0.9983316,0.0002646014,0.0006107707,0.0003385552,0.0002505667,0.000203914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002672062,0.01089804,0.005862995,0.0007411478,0.0005655118,0.00006437825,0.04700438,0.001459312,0.5865972,0.0004917363,0.05202597,0.2916172],"study_design_scores_gemma":[0.015747,0.0007581603,0.004576676,0.00008260416,0.0002505459,0.000009855941,0.0033443,0.009417614,0.5781254,0.0003910676,0.386472,0.0008247715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910613,0.00005107683,0.0006010236,0.001190494,0.001746872,0.003746913,0.00006895881,0.0003698286,0.001163516],"genre_scores_gemma":[0.9936178,0.000122435,0.000531332,0.0004641642,0.0002252035,0.001069054,0.000563105,0.00005215442,0.003354788],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3344461,"threshold_uncertainty_score":0.9998308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1664712180694004,"score_gpt":0.4490068162313977,"score_spread":0.2825355981619972,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}